glp 1 compounding restrictions Compounded GLP-1 Treatment FDA to Restrict Ingredients Used

(Check your label) 3

The medications have garnered both praise and criticism in recent years as their popularity has grown

(NYSE: HIMS), a publicly traded company headquartered in San Francisco, California

I feel great and have seen a significant shift in my mood

Despite Harvard Medical School research published in July 2024 showing diabetes patients prescribed semaglutide faced over four times higher NAION risk (and weight loss patients faced over seven times higher risk) Novo Nordisks current Ozempic and Wegovy labels still mention only generic vision changes without specifically identifying NAION or permanent blindness as known risks